NICEVIVA
MONOGRAPH SPEC LATEST 2026

Chaga Mushroom

BOTANICALS · Evidence Monograph

Chaga Mushroom is an evidence-graded botanicals monograph evaluated across 37 peer-reviewed PubMed studies (0 meta-analyses, 0 systematic reviews, and 0 randomized controlled trials). Current clinical evidence is rated GRADE Low (2.0 / 4.0) for phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways.

Evidence Grade (GRADE) Low (2.0 / 4.0)
Indexed PubMed Studies 37 Studies
Meta-Analyses · Reviews 0 Meta · 0 Systematic Reviews
Randomized Trials (RCT) 0 RCTs (0 Double-Blind)
Cumulative Participants 8 Quantitative Studies
Reported Trial Dosages 1 μg · 0.35 g · 740 μg
Trial Duration Range 14 days · 21 days · 85 days
Reading Time ~19 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways (supported by 37 indexed PubMed studies, GRADE Low).
  2. 02 Adults matching clinical trial dosing protocols (1 μg · 0.35 g · 740 μg) over a structured 14 days evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Standardized Marker-Compound Botanical Extract
Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Gradual physiological adaptation over 4–12 weeks without gastric burning or daytime sedation.
Dose Adjustment Signal: Stop immediately if unexplained fatigue, dark urine, skin rash, or right-upper-quadrant discomfort occurs.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
Immediately After Breakfast or Lunch
Post-meal administration buffers concentrated botanical tannins and organic acids against gastric mucosal irritation.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary botanicals clinical efficacy (37 PubMed studies)
Quantitative biomarker & outcome analysis (8 studies with effect-size/sample data)
Randomized controlled trial verification (0 RCTs · 0 double-blind)
Systematic review & meta-analysis synthesis (0 meta-analyses · 0 reviews)
01

What Is Chaga Mushroom & Why Does Form Matter?

Chaga Mushroom is classified under BOTANICALS and has been investigated across 37 peer-reviewed PubMed publications for its role in phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (1 μg, 0.35 g, 740 μg).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Chaga Mushroom frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (0 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Chaga Mushroom acts on pathways governing phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Chaga Mushroom an overall evidence rating of GRADE Low (2.0 / 4.0) based on 37 PubMed studies: 0 meta-analyses, 0 systematic reviews, and 0 randomized controlled trials (0 double-blind).

Representative peer-reviewed findings include: • PMID:39595631 (2024) — "Chaga Mushroom Triterpenoids Inhibit Dihydrofolate Reductase and Act Synergistically with Conventional Therapies in Breast Cancer." (Four highly bioactive triterpenoids (inotodiol, trametenolic acid, 3-hydroxy-lanosta-8,24-dien-21-al, and betulin) were identified as the main components, able to decrease BC cell viability and block the cell cycle in G0/G1 by inducing the downregulation of cyclin D1, CDK4, cycli) • PMID:41978174 (2026) — "Inonotus obliquus Polysaccharides: Preparation, Structural Characteristics, Structure-Activity Relationships, Biological Activities and Applications." (It aims to provide valuable theoretical references for the further development and practical application of IOPs in the fields of medicine and functional foods.) • PMID:41800303 (2026) — "The effects of polysaccharides from Inonotus obliquus, artemisinin, and dihydroartemisinin on the reproductive system of male mice infected with Neospora caninum." (Immunological assays confirmed decreased levels of immunoglobulin G1 (IgG1), IgG2a, interleukin (IL)-4, IL-6, tumor necrosis-α factor nitric oxide, and anti-sperm antibodies in the treatment groups.)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Standardized Marker-Compound Botanical Extract. Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 1 μg · 0.35 g · 740 μg · 54.3 mg over 14 days · 21 days · 85 days · 7 days. Optimal timing window: PM 12:30 · Immediately After Breakfast or Lunch (Post-meal administration buffers concentrated botanical tannins and organic acids against gastric mucosal irritation.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Gradual physiological adaptation over 4–12 weeks without gastric burning or daytime sedation.

Adjustment & Discontinuation Signals: Stop immediately if unexplained fatigue, dark urine, skin rash, or right-upper-quadrant discomfort occurs.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Chaga Mushroom, but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · Immediately After Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (1 μg · 0.35 g · 740 μg) and re-evaluate efficacy after 14 days.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (37 Studies) · 8 Quantitative Analyses

01
CLINICAL STUDY Biomolecules (2024) PMID: 39595631 ↗
Chaga Mushroom Triterpenoids Inhibit Dihydrofolate Reductase and Act Synergistically with Conventional Therapies in Breast Cancer.
Clinical Trial Synthesis 2024 Clinical Study published in Biomolecules. Key conclusion: Four highly bioactive triterpenoids (inotodiol, trametenolic acid, 3-hydroxy-lanosta-8,24-dien-21-al, and betulin) were identified as the main components, able to decrease BC cell viability and block the cell cycle in G0/G1 by inducing the downregulation of cyclin D1, CDK4, cycli
View Original PubMed Abstract ↓

Inonotus obliquus (Chaga) is a medicinal mushroom with several pharmacological properties that is used as a tea in traditional Chinese medicine. In this study, Chaga water extract was digested in vitro to mimic the natural processing and absorption of its biocomponents when it is consumed as functional beverage, and its anticancer activities were evaluated in breast cancer (BC) cell lines, representing HER2-positive and triple-negative subtypes. After chemical characterization by liquid chromatography/mass spectrometry (HR-QTOF) analysis, the effect of Chaga biocomponents on cell viability and cell cycle progression was assessed by MTT assay, FACS analysis, and Western blot. Dihydrofolate reductase (DHFR) activity was measured by an enzymatic assay. Four highly bioactive triterpenoids (inotodiol, trametenolic acid, 3-hydroxy-lanosta-8,24-dien-21-al, and betulin) were identified as the main components, able to decrease BC cell viability and block the cell cycle in G0/G1 by inducing the downregulation of cyclin D1, CDK4, cyclin E, and phosphorylated retinoblastoma protein. DHFR was identified as their crucial target. Moreover, bioactive Chaga components exerted a synergistic action with cisplatin and with trastuzumab in SK-BR-3 cells by inhibiting both HER2 and HER1 activation and displayed an immunomodulatory effect. Thus, Inonotus obliquus represents a source of triterpenoids that are effective against aggressive BC subtypes and display properties of targeted drugs.

02
CLINICAL STUDY Nutrients (2026) PMID: 41978174 ↗
Inonotus obliquus Polysaccharides: Preparation, Structural Characteristics, Structure-Activity Relationships, Biological Activities and Applications.
Clinical Trial Synthesis 2026 Clinical Study published in Nutrients. Key conclusion: It aims to provide valuable theoretical references for the further development and practical application of IOPs in the fields of medicine and functional foods.
View Original PubMed Abstract ↓

Inonotus obliquus, a rare medicinal and edible fungus, is rich in bioactive polysaccharides. These polysaccharides exhibit diverse biological activities, including gut microbiota-modulating, hypoglycemic, immunomodulatory, antitumor, antioxidant, hypolipidemic, and antiviral activities. Owing to these remarkable bioactivities and favorable safety profiles, Inonotus obliquus polysaccharides (IOPs) have garnered considerable research interest as promising candidates for the development of functional foods and therapeutic agents, particularly for the management of metabolic diseases and cancers. Based on the latest advances in the research on IOPs, this review summarizes its isolation and purification methods, structural characteristics, structure-activity relationships, biological properties and mechanisms, as well as their potential applications. It aims to provide valuable theoretical references for the further development and practical application of IOPs in the fields of medicine and functional foods.

03
CLINICAL STUDY Frontiers in veterinary science (2026) PMID: 41800303 ↗
The effects of polysaccharides from Inonotus obliquus, artemisinin, and dihydroartemisinin on the reproductive system of male mice infected with Neospora caninum.
Clinical Trial Synthesis 2026 Clinical Study published in Frontiers in veterinary science; statistical significance reported at p = 0.05. Key conclusion: Immunological assays confirmed decreased levels of immunoglobulin G1 (IgG1), IgG2a, interleukin (IL)-4, IL-6, tumor necrosis-α factor nitric oxide, and anti-sperm antibodies in the treatment groups.
View Original PubMed Abstract ↓

The present study investigated the protective effects of Inonotus obliquus polysaccharides (IOPs), artemisinin, and dihydroartemisinin (DHA) on Neospora caninum-induced damage of the reproductive system in male BALB/c mice. This study conducted in vivo resistance experiments against Neosporidium using three drugs: polysaccharides from Betula brownii, artemisinin, and dihydroartemisinin. On the basis of establishing a male mouse animal model of new sporidiosis, after gavage administration, the reproductive organ index of male mice was measured at 7d, 14d, 21d, 35d, and 42d, respectively. HE staining and transmission electron microscopy were used to observe the pathological changes of testicular and epididymal tissues. The improved Pap staining method was used to analyze sperm quality, flow cytometry was used to detect apoptosis of spermatogenic cells, MDA and ACP activities were measured, and ELISA was used to detect immunoglobulin IgG1, IgG2a, IgE, and cytokine IFN-γ, IL-4, IL-6, TNF-α. The qPCR method was used to detect the expression of apoptotic genes Bax, Bcl-2, Caspase-3, P53, as well as sperm related genes C-kit, Plzf, Sycp3, Stra8, Dnajb13, Mrto4, and Ipo11, as well as the levels of NO and AsAb. The results showed that IOPs and DHA exhibited significant anti-neosporal activity. Compared to infected mice, IOPs-treated mice showed significantly increased sperm density (p < 0.05) and sperm motility (p < 0.05), while DHA-treated mice exhibited a remarkably reduced sperm deformity rate (p < 0.05). Compared with the model group, the sperm motility in the ART-treated mice was significantl upregulated (p < 0.01). Histopathological analysis revealed that all three treatments ameliorated testicular and epididymal tissue damage, reduced mitochondrial vacuolization, and improved organ indices. Biochemical assays showed a reduced level of malondialdehyde and a high level of acid phosphatase activity in the testicular tissue of treated mice. Immunological assays confirmed decreased levels of immunoglobulin G1 (IgG1), IgG2a, interleukin (IL)-4, IL-6, tumor necrosis-α factor nitric oxide, and anti-sperm antibodies in the treatment groups. Gene expression analysis indicat

04
CLINICAL STUDY Journal of ethnopharmacology (2026) PMID: 41796618 ↗
Inonotus obliquus (Ach. ex Pers.) Pilát aqueous extract alleviates acute cold exposure/rewarming-induced myocardial injury by regulating mitochondrial dynamics via liver kinase B1/adenosine monophosphate-activated protein kinase/peroxisome proliferator-activated receptor gamma coactivator-1 alpha signaling pathway activation.
Clinical Trial Synthesis 2026 Clinical Study published in Journal of ethnopharmacology. Key conclusion: RESULTS: IOE significantly attenuated ACE/R-induced hemorheological abnormalities, cardiac dysfunction, and myocardial injury.
View Original PubMed Abstract ↓

ETHNOPHARMACOLOGICAL RELEVANCE: Acute cold exposure affects the cardiovascular system substantially. Inonotus obliquus (Ach. ex Pers.) Pilát (IO), commonly referred to as "Chaga" in Russian traditional medicine, is a fungus that primarily parasitizes birch trees in cold climate regions. IO is extensively employed in Russian folk medicine for the treatment of cardiovascular diseases, including hypertension, hyperlipidemia, atherosclerosis, and symptoms of coronary heart disease. It is purported to holistically modulate cardiovascular function. However, despite the widespread use of I. obliquus aqueous extract (IOE), its cardioprotective effects against acute cold exposure/rewarming (ACE/R)-induced myocardial injury are yet to be elucidated. AIM OF THE STUDY: To assess the cardioprotective efficacy of IOE against ACE/R-induced myocardial injury in rats and to elucidate its underlying mechanism of action. MATERIALS AND METHODS: An ACE/R injury model was established by exposing rats to a temperature of -15 °C for 6 h, and then rewarming them to a temperature of 24 °C for 12 h. The rats were administered IOE (300 and 600 mg/kg) or 0.5% CMC-Na (vehicle control) via the intragastric route for 7 consecutive days prior to acute cold exposure. The ACE/R model was established 1 h after the final administration. Cardiac function, hemorheological parameters, myocardial histopathology, and serum levels of myocardial injury markers were assessed to evaluate the cardioprotective efficacy of IOE against ACE/R. Subsequently, in vivo transcriptomic analyses were performed to elucidate the underlying mechanism of IOE. To assess the expression levels of proteins and genes related to mitochondrial dynamics, mitochondrial function, energy metabolism, and the LKB1/AMPK/PGC-1α signaling pathway, western blotting and qRT-PCR were performed. RESULTS: IOE significantly attenuated ACE/R-induced hemorheological abnormalities, cardiac dysfunction, and myocardial injury. Transcriptomic sequencing analyses revealed the cardioprotective effects of IOE to be potentially mediated via regulation of mitochondrial dynamics and function. Western blotting and qRT-PCR analyses further confirmed that IOE

05
CLINICAL STUDY Current issues in molecular biology (2026) PMID: 41751415 ↗
A Water Extract of Mixed Mushroom Mycelia Mitigates Cognitive Deficit and Oxidative Stress After Global Cerebral Ischemia-Reperfusion Injury.
Clinical Trial Synthesis 2026 Clinical Study published in Current issues in molecular biology. Key conclusion: CONCLUSIONS: These findings suggest that GMK confers dose-dependent behavioral and histopathological protection against GCIRI, potentially by modulating redox- and apoptosis-related signaling (Bax/Bcl-2, GPX/CAT, and ERK/iNOS pathways), with more consistent effects at a higher do
View Original PubMed Abstract ↓

BACKGROUND: GMK is a bioactive material newly identified from a water extract of mixed mushroom mycelia (Phellinus linteus, Inonotus obliquus, and Ganoderma lucidum). It has shown protective effects against glutamate-induced excitotoxicity and lipopolysaccharide-triggered neuroinflammation. However, whether GMK can ameliorate global cerebral ischemia-reperfusion injury (GCIRI) and its associated cognitive deficit remains to be elucidated. METHODS: GCIRI was induced in male Sprague-Dawley rats by bilateral common carotid artery occlusion with hypovolemia (BCCAO/H). GMK (30 or 90 mg/kg, p.o.) was administered once daily for 14 days before surgery. Cognitive functions were evaluated using the Y-maze, Barnes maze, and passive avoidance tests. Hippocampal CA1 neuronal survival and glial activation were analyzed by cresyl violet staining and Iba1/GFAP immunohistochemistry. In parallel, PC12 cells were pretreated with GMK (100 or 200 μg/mL, 24 h) before oxygen-glucose deprivation and reoxygenation (OGD/R), and apoptosis (TUNEL, Bax/Bcl-2), oxidative stress markers (ROS, MDA, and NO), antioxidant enzymes including glutathione peroxidase (GPX) and catalase (CAT), and signaling proteins (p-ERK/ERK, iNOS) were examined. RESULTS: GMK significantly ameliorated GCIRI-induced learning and memory impairments, protected CA1 pyramidal neurons, and reduced microglial and astrocytic activation. In OGD/R-challenged PC12 cells, GMK attenuated apoptosis, suppressed ROS, MDA, and NO production, normalized GPX and CAT activities, and favorably regulated p-ERK and iNOS pathways. CONCLUSIONS: These findings suggest that GMK confers dose-dependent behavioral and histopathological protection against GCIRI, potentially by modulating redox- and apoptosis-related signaling (Bax/Bcl-2, GPX/CAT, and ERK/iNOS pathways), with more consistent effects at a higher dose.

06
CLINICAL STUDY Antioxidants (Basel, Switzerland) (2026) PMID: 41750647 ↗
Three Polyphenolic Compounds from Inonotus obliquus: Antioxidant Activity, Xanthine Oxidase Inhibition, and Regulatory Effects on MyD88/TLR4/NF-κB Pathway in MSU-Induced RAW 264.7 Macrophages.
Clinical Trial Synthesis 2026 Clinical Study published in Antioxidants (Basel, Switzerland); statistical significance reported at p = 0.05. Key conclusion: obliquus crude extract significantly reduced ROS, NO, LDH, and cytokines (p < 0.05), increased SOD, and downregulated TLR4, MyD88, and NF-κB expression.
View Original PubMed Abstract ↓

BACKGROUND: Inonotus obliquus (Chaga), a medicinal and edible macrofungus abundant in bioactive polyphenols, is a potential source of natural antioxidants and anti-inflammatory agents for functional foods. This study aimed to evaluate the antioxidant capacity of three key polyphenols (osmundacetone [OS], protocatechuic aldehyde [PAH], protocatechuic acid [PA]) from I. obliquus and decipher their anti-inflammatory mechanisms via the MyD88/TLR4/NF-κB pathway in a gout-related model. METHODS: Antioxidant activity was assessed by xanthine oxidase (XO) inhibition (IC50), superoxide anion (O2-) scavenging, and structure-activity relationship (SAR) analysis; in a monosodium urate (MSU)-induced acute gout cell model, reactive oxygen species (ROS), nitric oxide (NO), lactate dehydrogenase (LDH), superoxide dismutase (SOD), pro-inflammatory cytokines (TNF-α, IL-1β) were quantified, and MyD88/TLR4/NF-κB pathway proteins were analyzed by Western blot. RESULTS: OS showed the strongest XO inhibition (IC50 = 4.91 mM), followed by PAH (IC50 = 5.92 mM) and PA (IC50 = 26.53 mM); OS exerted dual redox effects by scavenging O2- and suppressing XO-mediated O2- generation, with its conjugated C=C-carbonyl system and PAH's aldehyde group enhancing XO binding. All polyphenols and I. obliquus crude extract significantly reduced ROS, NO, LDH, and cytokines (p < 0.05), increased SOD, and downregulated TLR4, MyD88, and NF-κB expression. CONCLUSIONS: I. obliquus-derived polyphenols exhibit obvious antioxidant and xanthine oxidase inhibitory effects, and regulate oxidative stress, pro-inflammatory mediators, and the MyD88/TLR4/NF-κB signaling pathway in monosodium urate-stimulated RAW 264.7 inflammatory macrophages, supporting their development as natural functional food ingredients and potential candidates for gout-related and oxidative stress-associated inflammatory cellular disorders.

07
CLINICAL STUDY International journal of biological macromolecules (2026) PMID: 41724299 ↗
Preparation, bioactivities, structure-activity relationships, applications, and safety concerns of Inonotus obliquus polysaccharides: A review.
Clinical Trial Synthesis 2026 Clinical Study published in International journal of biological macromolecules. Key conclusion: Practical criteria for raw-material selection and key extraction parameters are further outlined to promote standardized preparation and improve inter-study reproducibility.
View Original PubMed Abstract ↓

Inonotus obliquus polysaccharides (IOPs) are β-glucan-rich heteropolysaccharides whose structural diversity underlies their immunomodulatory, antioxidant, and gut-organ-axis-mediated activities. This review synthesizes recent advances in IOPs extraction, purification, and structural characterization, clarifying how molecular weight distribution, monosaccharide composition, glycosidic linkage patterns, branching topology, and triple-helix integrity collectively determine biological performance. Emerging green extraction technologies-such as subcritical water and enzyme-assisted approaches-have improved yield while better preserving native structural features. Practical criteria for raw-material selection and key extraction parameters are further outlined to promote standardized preparation and improve inter-study reproducibility. By integrating current knowledge and refining understanding of IOPs structure-activity relationships, this review seeks to identify critical knowledge gaps and suggest directions for future research and development, including the optimization of extraction strategies, integration of multi-omics technologies to deepen structure-activity elucidation, and expansion of IOPs applications in food, biomedical, and sustainable material fields.

08
CLINICAL STUDY Scientific reports (2026) PMID: 41714705 ↗
Fungal extracts influence lifespan and immune responses in the Carniolan honey bee (Apis mellifera carnica, Pollmann 1879).
Clinical Trial Synthesis 2026 Clinical Study published in Scientific reports; statistical significance reported at p = 0.0001. Key conclusion: This study demonstrates that including fungal extracts in the bee diet improves immune indicators in honey bees.
View Original PubMed Abstract ↓

Various stressors reduce the health of honey bees (Apis mellifera) and colony survival. Therefore, there is an ongoing search for substances that strengthen bee immunity. Fungal extracts, which exhibit antimicrobial and antioxidant properties and mitigate viral infections, may prove to be such substances. The aim of this study was to determine how fungal extracts from Ganoderma lucidum (GL), Hericium erinaceus (HE), Inonotus obliquus (IO), and Trametes versicolor (TV) affect Carniolan honey bee longevity, antioxidant activity (CAT, GPx, GST, SOD, and TAC levels) and metabolic marker activity (ALP, ALT, and AST). Haemolymph for biochemical analyses was collected from bees at 7, 14, and 21 days after exposure to fungal extracts and stored at - 25 °C until analysis. GL treatment increased bee longevity by 16.4% compared to untreated bees (p < 0.0001). Bees fed with fungal extracts showed increased activities of metabolic markers and antioxidants after 14 and 21 days compared to bees only fed sugar syrup (p < 0.0001). Among all groups, bees fed IO had the highest levels of markers and antioxidants. This study demonstrates that including fungal extracts in the bee diet improves immune indicators in honey bees. © 2026. The Author(s).

09
CLINICAL STUDY International journal of medicinal mushrooms (2026) PMID: 41662656 ↗
Mushrooms and Their Bioactive Ingredients as Natural Resources for Development of Innovative Skin Care Formulations and Products.
Clinical Trial Synthesis 2026 Clinical Study published in International journal of medicinal mushrooms. Key conclusion: The risk associated with synthetic chemicals in cosmetics was realized by consumers and this awareness led to the demand for natural products-based cosmetics.
View Original PubMed Abstract ↓

Glowing skin is the aspiration of individuals especially women for enhancing the beauty and charm. Modern lifestyle attaches significant importance to skin care. Hence the cosmetic industry is paying immense attention to cosmetic product development. Cosmetic industry is one of the fastest growing industries in the world in recent years. Majority of cosmetics contain synthetics as well as natural compounds. The risk associated with synthetic chemicals in cosmetics was realized by consumers and this awareness led to the demand for natural products-based cosmetics. As a result, cosmetic industries are compelled to pay adequate attention to raw materials from natural sources. Traditionally plants have been exploited for cosmetic product formulations. One of the natural resources that has caught the attention of cosmetic industry in recent years is the mushrooms. They are known to have strong antioxidant, antibacterial, anti-inflammatory, and tyrosinase, hyaluronidase, collagenase, and elastase inhibitory properties. Because of these attributes they are considered as multifunctional cosmetic bioactive ingredients. They have excellent antioxidant, antiaging, skin whitening, antiwrinkle and moisturizing properties. Common mushrooms frequently used in cosmetic formulation are Lentinula edodes, Grifola frondosa, Ganoderma lucidum, Cordyceps sinensis, Tremella fuciformis, Agaricus bisporus, Pleurotus ostreatus, Inonotus obliquus, and Hericium erinaceus. Mushroom based cosmetic products have substantial world market especially in USA, China, UK, Korea and Japan. Mushroom cosmetic market presents promising opportunities for expansion because of the growing demands of aging solutions. Global demand is predicted to reach nearly 3.9 billion USD by 2032. This review outlines the importance of mushrooms and their bioactive ingredients for development of skin care formulations and products in the multibillion-dollar cosmetic industry.

10
CLINICAL STUDY Bulletin of experimental biology and medicine (2025) PMID: 41656465 ↗
Antiviral Activity of Plant-Based Preparations against SARS-CoV-2 and Herpes Simplex Virus Type 2 In Vitro: A Review of Experimental Findings.
Clinical Trial Synthesis 2025 Clinical Study published in Bulletin of experimental biology and medicine. Key conclusion: These findings may serve as a basis both for the identification of individual bioactive plant-derived compounds and for the development of cost-effective therapeutic or prophylactic agents against COVID-19 and for reducing the recurrence rate of chronic genital herpes.
View Original PubMed Abstract ↓

We reviewed published data on the efficacy of plant-derived preparations, including the authors' original in vitro findings on the antiviral activity of aqueous and dry ethanol extracts against the RNA virus SARS-CoV-2 and the DNA virus herpes simplex virus type 2 (HSV-2). The study evaluates the activity of an aqueous extract prepared from fermented leaves of Epilobium angustifolium L., as well as dry ethanol extracts obtained from clove spice (Syzygium aromaticum L.), black and green tea (Camellia sinensis L.), leaves of Rhaponticum carthamoides, the basidiomycete fungus chaga (Inonotus obliquus (Ach. ex Pers.) Pil.), and four lichen species: Cetraria islandica L., Usnea L., Pseudevernia furfuracea L., and Cladonia stellaris Opiz. HPLC analysis of several dry ethanol extracts suggests that their antiviral activity may be attributed to polyphenolic compounds and ecdysteroids. These findings may serve as a basis both for the identification of individual bioactive plant-derived compounds and for the development of cost-effective therapeutic or prophylactic agents against COVID-19 and for reducing the recurrence rate of chronic genital herpes. © 2026. Springer Science+Business Media, LLC, part of Springer Nature.

RELATED MONOGRAPHS

Related Monographs in This Category